This phase 2 clinical trial (ReBUILD) evaluated the use of clemastine fumarate—a first-generation antihistamine capable of inducing oligodendrocyte differentiation—as a remyelinating therapy for patients with multiple sclerosis. Source: AAO
Renowned physician-leader Dr. Jerry A. Shields will be the inaugural recipient of the distinguished Brady-Shields Endowed Chair in Ocular Oncology. Source: AAO
In this multicenter study, the authors retrospectively identified predictors of treatment success in syphilitic uveitis. Source: AAO
The cost to restore sight to the blind will be a “responsible” $425,000 per eye, Spark Therapeutics announced this week. The company set the price of Luxturna and laid out options for insurers and patients to deal with the financial burden. Source: AAO
Investigators evaluated demographic and geographic patterns in the use of ranibizumab versus bevacizumab for newly diagnosed neovascular AMD among Medicare beneficiaries in the US. Source: AAO
This week, animal eye docs unbox a massive whale eye, a man mistakes superglue for eyedrops and Santen Pharmaceutical redoubles efforts to market a nonsteroidal drug for uveitis. Source: AAO
Investigators explored the effect of spaceflight on the anatomical configuration of the brain and in cerebrospinal fluid spaces. Source: AAO
Canadian drugmaker Valeant Pharmaceuticals announced the approval of the first over-the-counter medication containing low-dose brimonidine tartrate (Lumify) for the treatment of eye redness. Source: AAO
Tel: 518-580-0553
Get Directions »
Tel: 518-580-0553
Get Directions »
Tel: +1 (518) 580-0553
Get Directions »
